State Medicaid programs play a critical role in financing pharmacologic and non-pharmacologic treatments for opioid use disorder (OUD) as they provide coverage for 4 in 10 individuals with OUD. States are currently taking myriad approaches to address the opioid crisis by changing the way they regulate providers, pay for care, and cover evidence-based treatments in Medicaid. However, there exists no analytic infrastructure for learning about the impact of state policy experimentation on OUD treatment and outcomes as states have no mechanism for sharing data or measurement tools.
With funding from the National Institute on Drug Abuse (NIDA), AcademyHealth's Evidence-Informed State Health Policy Institute, in collaboration with the University of Pittsburgh, are engaging MODRN state-university partnerships in Delaware, Kentucky, Maryland, Michigan, North Carolina, Ohio, Pennsylvania, Tennessee, Virginia, West Virginia, Wisconsin, Maine, and Massachusetts to address this issue. These states account for over a quarter of the country's Medicaid enrollees, and the partnerships have access to complete and recent Medicaid data. Our objectives are to provide a comprehensive assessment of OUD treatment quality and outcomes in Medicaid and to inform policy decisions on coverage and payment for evidence-based OUD treatments in Medicaid.
This work is supported by a grant from the National Institute on Drug Abuse (NIDA) R01DA048029.
External Publications:
- Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018
JAMA, 2021 Jul 13;326(2):154-164. doi: 10.1001/jama.2021.7374. PMID: 34255008. - Outpatient Follow-Up and Use of Medications for Opioid Use Disorder after Residential Treatment Among Medicaid Enrollees in 10 States
Drug and Alcohol Dependence, 2022 Dec 1;241:109670. doi: 10.1016/j.drugalcdep.2022.109670. Epub 2022 Oct 21. PMID: 36332591. - Healthcare Patterns of Pregnant Women and Children Affected by OUD in 9 State Medicaid Populations
Journal of Addiction Medicine, 2021 Sep-Oct 01;15(5):406-413. doi: 10.1097/ADM.0000000000000780. PMID: 33560699 - Postpartum Follow-up Care for Pregnant Persons With Opioid Use Disorder and Hepatitis C Virus Infection
Obstetrics & Gynecology, 2022 May 1;139(5):916-918. doi: 10.1097/AOG.0000000000004760. Epub 2022 Apr 5. PMID: 35576352 - Follow-up after ED visits for opioid use disorder: Do they reduce future overdoses?
Journal of Substance Abuse Treatment, 2022 May 21:108807. doi: 10.1016/j.jsat.2022.108807. Online ahead of print. PMID: 35649885 - Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study
Addiction, 2022 Jun 2. doi: 10.1111/add.15959. Online ahead of print. PMID: 35652681 - Medicaid’s Role in Improving Substance Use Disorder Treatment
Milbank Memorial Fund Primer. September 25, 2020. - Issue Brief: Opioid Use Disorder among Medicaid Enrollees: Snapshot of the Epidemic and State Responses
Kaiser Family Foundation, November 15, 2019. - Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder
Journal of Substance Abuse Treatment. 2023 Jan; 144. https://doi.org/10.1016/j.jsat.2022.108921. - Prevalence of Testing for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Among Medicaid Enrollees Treated With Medications for Opioid Use Disorder
Clinical Infectious Diseases, 2023 May 24;76(10):1793-1801. doi: 10.1093/cid/ciac981. - Trends in Use of Medication to Treat Opioid Use Disorder During the COVID-19 Pandemic in 10 State Medicaid Programs
JAMA Health Forum. 2023 Jun 2;4(6):e231422. doi: 10.1001/jamahealthforum.2023.1422. - Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs
Drug and Alcohol Dependence, 2023 Jun 1;247:109868. doi: 10.1016/j.drugalcdep.2023.109868. Epub 2023 Apr 5. - Use of residential opioid use disorder treatment among Medicaid enrollees in nine states
Journal of Substance Use and Addiction Treatment, 2023 Jun;149:209034. doi: 10.1016/j.josat.2023.209034. Epub 2023 Apr 12. - Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states
Drug and Alcohol Dependence, 2023 Sep 1;250:110875. doi: 10.1016/j.drugalcdep.2023.110875. Epub 2023 Jun 24. - Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies
JAMA Health Forum, 2024 May 3;5(5):e241077. doi: 10.1001/jamahealthforum.2024.1077.